Tissue ingrowth materials and method of using the same
Implantable materials for use with end effectors like surgical stapling devices, and methods for using the same, are generally provided. In some embodiments, adjunct materials for use with surgical staplers are provided. For example, a kit for stapling tissue is provided that can include a surgical stapler having an end effector. The end effector can have first and second jaws. The kit can include an adjunct material having hydrophobic surface regions and hydrophilic surface regions and the adjunct material can be configured to mate to at least one of the jaws of the end effector. Other implants, devices, and methods for surgical stapling are also provided.
1. A surgical system comprising:
an adjunct including a biologic material and a synthetic material; and
a surgical staple cartridge;
wherein the synthetic material has a plurality of openings therein configured to allow components of the biologic material to pass therethrough;
the adjunct is configured to be mated to the surgical staple cartridge with the synthetic material directly contacting the surgical staple cartridge and with the biologic material facing away from the surgical staple cartridge; and
the adjunct is configured to be implanted in a body of a patient with the biologic material in contact with a tissue of the patient and with the synthetic material facing away from and not in contact with the tissue of the patient.
2. The surgical system of claim 1 , wherein the biologic material comprises a bioabsorbable membrane.
3. The surgical system of claim 1 , wherein the biologic material comprises an extracellular matrix.
4. The surgical system of claim 1 , wherein the biologic material comprises a patient-derived material including at least one of platelet enriched plasma, diced tissue fragments, fibrin, and stem cells.
5. The surgical system of claim 1 , wherein the biologic layer comprises at least one of platelet poor plasma (PPP), platelet rich plasma (PRP), starch, chitosan, alginate, fibrin, thrombin, polysaccharide, cellulose, collagen, bovine collagen, bovine pericardium, gelatin-resorcin-formalin adhesive, oxidized cellulose, mussel-based adhesive, poly (amino acid), agarose, polyetheretherketones, amylose, hyaluronan, hyaluronic acid, whey protein, cellulose gum, starch, gelatin, and silk.
6. The surgical system of claim 1 , wherein the synthetic layer comprises a polymer mesh.
7. The surgical system of claim 1 , wherein the synthetic layer comprises at least one of polydioxanone, Polyglycerol sebacate (PGS), PGA (Polyglycolic acid), PCL (Polycaprolactone), PLA or PLLA (Polylactic acid), PHA (polyhydroxyalkanoate), PGCL (poliglecaprone 25), PANACRYL, Polyglactin910, Poly glyconate, PGA/TMC (polyglycolide-trimethylene carbonate), polyhydroxybutyrate (PHB), poly(vinylpyrrolidone) (PVP), poly(vinyl alcohol) (PVA), and a blend of copolymerization of the PGA, PCL, PLA, PDS monomers.
8. The surgical system of claim 1 , wherein the surgical staple cartridge is configured to be coupled to a jaw of a surgical stapler.
9. The surgical system of claim 1 , further comprising a surgical end effector;
wherein the surgical staple cartridge is configured to be seated in the surgical end effector.
10. A surgical method comprising:
implanting an adjunct in a body of the patient with a biologic material of the adjunct in contact with a tissue of the patient and with a synthetic material of the adjunct facing away from and not in contact with the tissue of the patient;
wherein the synthetic material has a plurality of openings therein configured to allow components of the biologic material to pass therethrough;
the adjunct is implanted using a surgical stapler with the adjunct mated to a surgical staple cartridge with the synthetic material directly contacting the surgical staple cartridge and with the biologic material facing away from the surgical staple cartridge.
11. The method of claim 10 , wherein the synthetic material comprises at least one of polydioxanone, Polyglycerol sebacate (PGS), PGA (Polyglycolic acid), PCL (Polycaprolactone), PLA or PLLA (Polylactic acid), PHA (polyhydroxyalkanoate), PGCL (poliglecaprone 25), PANACRYL, Polyglactin910, Poly glyconate, PGA/TMC (polyglycolide-trimethylene carbonate), polyhydroxybutyrate (PHB), poly(vinylpyrrolidone) (PVP), poly(vinyl alcohol) (PVA), and a blend of copolymerization of the PGA, PCL, PLA, PDS monomers.
12. The method of claim 10 , wherein the biologic material comprises a patient-derived material including at least one of platelet enriched plasma, diced tissue fragments, fibrin, and stem cells.
13. A method of manufacturing comprising:
treating a surface of a hydrophobic synthetic material to form a hydrophilic portion including pockets formed in the surface;
wherein the hydrophilic portion is configured to encourage cellular ingrowth; and
the treated synthetic material is configured to be implanted in a body of a patient with a surface of the hydrophilic portion including the pockets formed therein in contact with a tissue of the patient and with an opposite, hydrophobic surface of the treated synthetic material facing away from and not in contact with the tissue of the patient.
14. The method of claim 13 , wherein the surface of the hydrophobic synthetic material is treated with an acid or base.
15. The method of claim 14 , further comprising removing the acid or base from the synthetic material after the pockets have been formed and before the treated synthetic material is implanted in the body of the patient.
16. The method of claim 13 , further comprising mating the treated synthetic material to a surgical staple cartridge;
wherein the treated synthetic material directly contacts the surgical staple cartridge with the hydrophilic portion facing away from the surgical staple cartridge.
17. The method of claim 13 , further comprising mating the treated synthetic material to a jaw of an end effector of a surgical stapler;
wherein the treated synthetic material directly contacts the jaw with the hydrophilic portion facing away from the jaw.
18. The method of claim 13 , wherein the synthetic material includes an absorbable polymer.
19. The method of claim 13 , wherein the synthetic material is a polylactic acid (PLA)/polycaprolactone (PCL) copolymer.
20. The method of claim 13 , wherein the hydrophobic polymer is a polyglycolic acid (PGA)/polycaprolactone (PCL) copolymer having polyethylene glycol and/or poloxamer repeat units.